Payment overview · 2025
General Payments
$16.56
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ben Liscano, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, SD · NPI 1326301128
Verified facts
What the public records show
CMS Open Payments records show Ben Liscano, MD received $16.56 in general payments during 2025 across 1 reported records.
Medtronic, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.56 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 101 |
| Furosemide | Furosemide | 440 | 74 |
| Omeprazole | Omeprazole | 389 | 67 |
| Losartan Potassium | Losartan Potassium | 373 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 65 |
| Lisinopril | Lisinopril | 315 | 53 |
| Gabapentin | Gabapentin | 243 | 37 |
| Potassium Chloride | Potassium Chloride | 243 | 36 |
| Eliquis | Apixaban | 206 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 34 |
| Metformin Hcl | Metformin Hcl | 167 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 27 |
| Simvastatin | Simvastatin | 161 | 28 |
| Jantoven | Warfarin Sodium | 150 | 23 |
| Sertraline Hcl | Sertraline Hcl | 126 | 19 |
| Carvedilol | Carvedilol | 124 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 18 |
| Mirtazapine | Mirtazapine | 107 | 14 |
| Xarelto | Rivaroxaban | 102 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 23 |
| Allopurinol | Allopurinol | 95 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 16 |
| Metformin Hcl Er | Metformin Hcl | 84 | 16 |
| Tramadol Hcl | Tramadol Hcl | 84 | 16 |
| Spironolactone | Spironolactone | 81 | 15 |
| Warfarin Sodium | Warfarin Sodium | 77 | 12 |
| Myrbetriq | Mirabegron | 75 | suppressed |
| Famotidine | Famotidine | 74 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 12 |
| Atenolol | Atenolol | 68 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 11 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Baclofen | Baclofen | 54 | suppressed |
| Metolazone | Metolazone | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Meloxicam | Meloxicam | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Digoxin | Digoxin | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 16 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 11 |
| Prednisone | Prednisone | 29 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Mesalamine Er | Mesalamine | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Ramipril | Ramipril | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.56 · 1 records | Medtronic, Inc. | MINIMED 780G | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error